Impact of differential cyclin D1 expression and localisation in prostate cancer

British Journal of Cancer

Volumn 96, Issue 6, 2007, Pages 970-979

  Comstock, C E S ^a   Revelo, M P ^a   Buncher, C R ^a   Knudsen, K E ^a  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

Androgen receptor; Cytoplasmic; Ki 67; p21Cip1; Proliferation; Prostate specific antigen

Indexed keywords

CYCLIN D1; CYCLIN DEPENDENT KINASE INHIBITOR 1; KI 67 ANTIGEN; PROSTATE SPECIFIC ANTIGEN; TUMOR MARKER;

ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MALE; PHENOTYPE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN LOCALIZATION;

ADENOCARCINOMA; CYCLIN D1; CYCLIN-DEPENDENT KINASE INHIBITOR P21; DISEASE PROGRESSION; HUMANS; KI-67 ANTIGEN; LYMPHATIC METASTASIS; MALE; NEOPLASM METASTASIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 33947431620     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6603615     Document Type: Article

References (89)

1. Aaltomaa S, Eskelinen M, Lipponen P (1999) Expression of cyclin A and D proteins in prostate cancer and their relation to clinicopathological variables and patient survival. Prostate 38: 175-182
2. Agus DB, Cordon-Cardo C, Fox W, Drobnjak M, Koff A, Golde DW et al. (1999) Prostate cancer cell cycle regulators: response to androgen withdrawal and development of androgen independence. J Natl Cancer Inst 91: 1869-1876
3. Alao JP, Gamble SC, Stavropoulou AV, Pomeranz KM, Lam EW, Coombes RC et al. (2006) The cyclin D1 proto-oncogene is sequestered in the cytoplasm of mammalian cancer cell lines. Mol Cancer 5: 7
4. Alt JR, Cleveland JL, Hannink M, Diehl JA (2000) Phosphorylation- dependent regulation of cyclin D1 nuclear export and cyclin D1-dependent cellular transformation. Genes Dev 14: 3102-3114
5. Alt JR, Gladden AB, Diehl JA (2002) p21(Cip1) Promotes cyclin D1 nuclear accumulation via direct inhibition of nuclear export. J Biol Chem 277: 8517-8523
6. Arnold A, Papanikolaou A (2005) Cyclin D1 in breast cancer pathogenesis. J Clin Oncol 23: 4215-4224
7. Asatiani E, Gelmann EP (2005) Targeted therapies for prostate cancer. Expert Opin Ther Targets 9: 283-298
8. Balasenthil S, Sahin AA, Barnes CJ, Wang RA, Pestell RG, Vadlamudi RK et al. (2004) p21-activated kinase-1 signaling mediates cyclin D1 expression in mammary epithelial and cancer cells. J Biol Chem 279: 1422-1428
9. Baretton GB, Klenk U, Diebold J, Schmeller N, Lohrs U (1999) Proliferation- and apoptosis-associated factors in advanced prostatic carcinomas before and after androgen deprivation therapy: prognostic significance of p21/WAF1/CIP1 expression. Br J Cancer 80: 546-555
10. Barr SM, Johnson EM (2001) Ras-induced colony formation and anchorage-independent growth inhibited by elevated expression of Puralpha in NIH3T3 cells. J Cell Biochem 81: 621-638
11. Bigoni R, Negrini M, Veronese ML, Cuneo A, Castoldi GL, Croce CM (1996) Characterization of t(11;14) translocation in mantle cell lymphoma by fluorescent in situ hybridization. Oncogene 13: 797-802
12. Bubendorf L, Kononen J, Koivisto P, Schraml P, Moch H, Gasser TC et al. (1999) Survey of gene amplifications during prostate cancer progression by high-throughout fluorescence in situ hybridization on tissue microarrays. Cancer Res 59: 803-806
13. Buckley MF, Sweeney KJ, Hamilton JA, Sini RL, Manning DL, Nicholson RI et al. (1993) Expression and amplification of cyclin genes in human breast cancer. Oncogene 8: 2127-2133
14. Burd CJ, Morey LM, Knudsen KE (2006a) Androgen receptor corepressors and prostate cancer. Endocr Relat Cancer 13: 1-17
15. Burd CJ, Petre CE, Moghadam H, Wilson EM, Knudsen KE (2005) Cyclin D1 binding to the androgen receptor (AR) NH2-terminal domain inhibits activation function association and reveals dual roles for AR corepression. Mol Endocrinol 19: 607-620
16. Burd CJ, Petre CE, Morey LM, Wang Y, Revelo MP, Haiman CA et al. (2006b) Cyclin D1b variant influences prostate cancer growth through aberrant androgen receptor regulation. Proc Natl Acad Sci USA 103: 2190-2195
17. Catalona WJ, Loeb S (2005) The PSA era is not over for prostate cancer. Eur Urol 48: 541-545
18. Chen CD, Welsbie DS, Tran C, Baek SH, Chen R, Vessella R et al. (2004) Molecular determinants of resistance to antiandrogen therapy. Nat Med 10: 33-39
19. Cheng M, Olivier P, Diehl JA, Fero M, Roussel MF, Roberts JM et al. (1999) The p21(Cip1) and p27(Kip1) CDK 'inhibitors' are essential activators of cyclin D-dependent kinases in murine fibroblasts. EMBO J 18: 1571-1583
20. Chhieng C, Cranor M, Lesser ME, Rosen PP (1998) Metaplastic carcinoma of the breast with osteocartilaginous heterologous elements. Am J Surg Pathol 22: 188-194
21. Coqueret O (2002) Linking cyclins to transcriptional control. Gene 299: 35-55
22. Culhaci N, Sagol O, Karademir S, Astarcioglu H, Astarcioglu I, Soyturk M et al. (2005) Expression of transforming growth factor-beta-1 and p27Kip1 in pancreatic adenocarcinomas: relation with cell-cycle-associated proteins and clinicopathologic characteristics. BMC Cancer 5: 98
23. Dhar KK, Branigan K, Parkes J, Howells RE, Hand P, Musgrove C et al. (1999) Expression and subcellular localization of cyclin D1 protein in epithelial ovarian tumour cells. Br J Cancer 81: 1174-1181
24. Diehl JA, Cheng M, Roussel MF, Sherr CJ (1998) Glycogen synthase kinase-3beta regulates cyclin D1 proteolysis and subcellular localization. Genes Dev 12: 3499-3511
25. Diehl JA, Sherr CJ (1997) A dominant-negative cyclin D1 mutant prevents nuclear import of cyclin-dependent kinase 4 (CDK4) and its phosphorylation by CDK-activating kinase. Mol Cell Biol 17: 7362-7374
26. Drobnjak M, Osman I, Scher HI, Fazzari M, Cordon-Cardo C (2000) Overexpression of cyclin D1 is associated with metastatic prostate cancer to bone. Clin Cancer Res 6: 1891-1895
27. Dworakowska D, Jassem E, Jassem J, Boltze C, Wiedorn KH, Dworakowski R et al. (2005) Prognostic value of cyclin D1 overexpression in correlation with pRb and p53 status in non-small cell lung cancer (NSCLC). J Cancer Res Clin Oncol 131: 479-485
28. El Gedaily A, Bubendorf L, Willi N, Fu W, Richter J, Moch H et al. (2001) Discovery of new DNA amplification loci in prostate cancer by comparative genomic hybridization. Prostate 46: 184-190
29. Elledge RM, Allred DC (1998) Prognostic and predictive value of p53 and p21 in breast cancer. Breast Cancer Res Treat 52: 79-98
30. Epstein JI, Allsbrook Jr WC, Amin MB, Egevad LL (2006) Update on the Gleason grading system for prostate cancer: results of an international consensus conference of urologic pathologists. Adv Anat Pathol 13: 57-59
31. Ewen ME, Lamb J (2004) The activities of cyclin D1 that drive tumorigenesis. Trends Mol Med 10: 158-162
32. Faglia G, Spada A (2001) Genesis of pituitary adenomas: state of the art. J Neurooncol 54: 95-110
33. Feldman BJ, Feldman D (2001) The development of androgen-independent prostate cancer. Nat Rev Cancer 1: 34-45
34. Fizazi K, Martinez LA, Sikes CR, Johnston DA, Stephens LC, McDonnell TJ et al. (2002) The association of p21((WAF-1/CIP1)) with progression to androgen-independent prostate cancer. Clin Cancer Res 8: 775-781
35. Fribourg AF, Knudsen KE, Strobeck MW, Lindhorst CM, Knudsen ES (2000) Differential requirements for ras and the retinoblastoma tumor suppressor protein in the androgen dependence of prostatic adenocarcinoma cells. Cell Growth Differ 11: 361-372
36. Fu M, Wang C, Li Z, Sakamaki T, Pestell RG (2004) Minireview: Cyclin D1: normal and abnormal functions. Endocrinology 145: 5439-5447
37. Gao W, Bohl CE, Dalton JT (2005) Chemistry and structural biology of androgen receptor. Chem Rev 105: 3352-3370
38. Germain D, Russell A, Thompson A, Hendley J (2000) Ubiquitination of free cyclin D1 is independent of phosphorylation on threonine 286. J Biol Chem 275: 12074-12079
39. Gladden AB, Diehl JA (2005) Location, location, location: The role of cyclin D1 nuclear localization in cancer. J Cell Biochem
40. Gumbiner LM, Gumerlock PH, Mack PC, Chi SG, deVere White RW, Mohler JL et al. (1999) Overexpression of cyclin D1 is rare in human prostate carcinoma. Prostate 38: 40-45
41. Haag P, Bektic J, Bartsch G, Klocker H, Eder IE (2005) Androgen receptor down regulation by small interference RNA induces cell growth inhibition in androgen sensitive as well as in androgen independent prostate cancer cells. J Steroid Biochem Mol Biol
42. Han EK, Lim JT, Arber N, Rubin MA, Xing WQ, Weinstein IB (1998) Cyclin D1 expression in human prostate carcinoma cell lines and primary tumors. Prostate 35: 95-101
43. Handa K, Yamakawa M, Takeda H, Kimura S, Takahashi T (1999) Expression of cell cycle markers in colorectal carcinoma: superiority of cyclin A as an indicator of poor prognosis. Int J Cancer 84: 225-233
44. Hibberts NA, Simpson DJ, Bicknell JE, Broome JC, Hoban PR, Clayton RN et al. (1999) Analysis of cyclin D1 (CCND1) allelic imbalance and overexpression in sporadic human pituitary tumors. Clin Cancer Res 5: 2133-2139
45. Holland TA, Elder J, McCloud JM, Hall C, Deakin M, Fryer AA et al. (2001) Subcellular localisation of cyclin D1 protein in colorectal tumours is associated with p21(WAF1/CIP1) expression and correlates with patient survival. Int J Cancer 95: 302-306
46. Jemal A, Siegel R, Ward E, Murray T, Xu J, Smigal C et al. (2006) Cancer statistics, 2006. CA Cancer J Clin 56: 106-130
47. Jiang W, Zhang YJ, Kahn SM, Hollstein MC, Santella RM, Lu SH et al. (1993) Altered expression of the cyclin D1 and retinoblastoma genes in human esophageal cancer. Proc Natl Acad Sci USA 90: 9026-9030
48. Kallakury BV, Sheehan CE, Ambros RA, Fisher HA, Kaufman Jr RP, Ross JS (1997) The prognostic significance of p34cdc2 and cyclin D1 protein expression in prostate adenocarcinoma. Cancer 80: 753-763
49. Khor TO, Gul YA, Ithnin H, Seow HF (2006) A comparative study of the expression of Wnt-1, WISP-1, survivin and cyclin-D1 in colorectal carcinoma. Int J Colorectal Dis 21: 291-300
50. Knudsen KE, Arden KC, Cavenee WK (1998) Multiple G1 regulatory elements control the androgen-dependent proliferation of prostatic carcinoma cells. J Biol Chem 273: 20213-20222
51. Knudsen KE, Cavenee WK, Arden KC (1999) D-type cyclins complex with the androgen receptor and inhibit its transcriptional transactivation ability. Cancer Res 59: 2297-2301
52. Kolar Z, Murray PG, Scott K, Harrison A, Vojtesek B, Dusek J (2000) Relation of Bcl-2 expression to androgen receptor, p21WAF1/CIP1, and cyclin D1 status in prostate cancer. Mol Pathol 53: 15-18
53. Kuramochi J, Arai T, Ikeda S, Kumagai J, Uetake H, Sugihara K (2006) High Pin1 expression is associated with tumor progression in colorectal cancer. J Surg Oncol 94: 155-160
54. Lin HM, Zhao L, Cheng SY (2002) Cyclin D1 Is a Ligand-independent Corepressor for Thyroid Hormone Receptors. J Biol Chem 277: 28733-28741
55. Lin X, Gelman IH (2002) Calmodulin and cyclin D anchoring sites on the Src-suppressed C kinase substrate, SSeCKS. Biochem Biophys Res Commun 290: 1368-1375
56. Linja MJ, Porkka KP, Kang Z, Savinainen KJ, Janne OA, Tammela TL et al. (2004) Expression of androgen receptor coregulators in prostate cancer. Clin Cancer Res 10: 1032-1040
57. Ljung G, Egevad L, Norberg M, Holmberg L, Nilsson S, Busch C (1997) Expression of p21 and mutant p53 gene products in residual prostatic tumor cells after radical radiotherapy. Prostate 32: 99-105
58. Lu F, Gladden AB, Diehl JA (2003) An alternatively spliced cyclin D1 isoform, cyclin D1b, is a nuclear oncogene. Cancer Res 63: 7056-7061
59. Lu S, Liu M, Epner DE, Tsai SY, Tsai MJ (1999) Androgen regulation of the cyclin-dependent kinase inhibitor p21 gene through an androgen response element in the proximal promoter. Mol Endocrinol 13: 376-384
60. Lukas J, Bartkova J, Rohde M, Strauss M, Bartek J (1995) Cyclin D1 is dispensable for G1 control in retinoblastoma gene-deficient cells independently of cdk4 activity. Mol Cell Biol 15: 2600-2611
61. MacGrogan D, Bookstein R (1997) Tumour suppressor genes in prostate cancer. Semin Cancer Biol 8: 11-19
62. Majumder PK, Sellers WR (2005) Akt-regulated pathways in prostate cancer. Oncogene 24: 7465-7474
63. Matsushima H, Sasaki T, Goto T, Hosaka Y, Homma Y, Kitamura T et al. (1998) Immunohistochemical study of p21WAF1 and p53 proteins in prostatic cancer and their prognostic significance. Hum Pathol 29: 778-783
64. McKay JA, Douglas JJ, Ross VG, Curran S, Murray GI, Cassidy J et al. (2000) Cyclin D1 protein expression and gene polymorphism in colorectal cancer. Aberdeen Colorectal Initiative. Int J Cancer 88: 77-81
65. Mittnacht S (1998) Control of pRB phosphorylation. Curr Opin Genet Dev 8: 21-27
66. Murphy C, McGurk M, Pettigrew J, Santinelli A, Mazzucchelli R, Johnston PG et al. (2005) Nonapical and cytoplasmic expression of interleukin-8, CXCR1, and CXCR2 correlates with cell proliferation and microvessel density in prostate cancer. Clin Cancer Res 11: 4117-4127
67. Nadal A, Cardesa A (2003) Molecular biology of laryngeal squamous cell carcinoma. Virchows Arch 442: 1-7
68. Omar EA, Behlouli H, Chevalier S, Aprikian AG (2001) Relationship of p21(WAF-I) protein expression with prognosis in advanced prostate cancer treated by androgen ablation. Prostate 49: 191-199
69. Osman I, Drobnjak M, Fazzari M, Ferrara J, Scher HI, Cordon-Cardo C (1999) Inactivation of the p53 pathway in prostate cancer: impact on tumor progression. Clin Cancer Res 5: 2082-2088
70. Palmqvist R, Stenling R, Oberg A, Landberg G (1998) Expression of cyclin D1 and retinoblastoma protein in colorectal cancer. Eur J Cancer 34: 1575-1581
71. Parry D, Mahony D, Wills K, Lees E (1999) Cyclin D-CDK subunit arrangement is dependent on the availability of competing INK4 and p21 class inhibitors. Mol Cell Biol 19: 1775-1783
72. Petre-Draviam CE, Cook SL, Burd CJ, Marshall TW, Wetherill YB, Knudsen KE (2003) Specificity of cyclin D1 for androgen receptor regulation. Cancer Res 63: 4903-4913
73. Petre-Draviam CE, Williams EB, Burd CJ, Gladden A, Moghadam H, Meller J et al. (2005) A central domain of cyclin D1 mediates nuclear receptor corepressor activity. Oncogene 24: 431-444
74. Radu A, Neubauer V, Akagi T, Hanafusa H, Georgescu MM (2003) PTEN induces cell cycle arrest by decreasing the level and nuclear localization of cyclin D1. Mol Cell Biol 23: 6139-6149
75. Reutens AT, Fu M, Wang C, Albanese C, McPhaul MJ, Sun Z et al. (2001) Cyclin D1 binds the androgen receptor and regulates hormone-dependent signaling in a p300/CBP-associated factor (P/CAF)-dependent manner. Mol Endocrinol 15: 797-811
76. Rigaud J, Tiguert R, Decobert M, Hovington H, LaTulippe E, Laverdiere J et al. (2004) Expression of p21 cell cycle protein is an independent predictor of response to salvage radiotherapy after radical prostatectomy. Prostate 58: 269-276
77. Sarkar FH, Li Y, Sakr WA, Grignon DJ, Madan SS, Wood Jr DP et al. (1999) Relationship of p21(WAF1) expression with disease-free survival and biochemical recurrence in prostate adenocarcinomas (PCa). Prostate 40: 256-260
78. Sato Y, Itoh F, Hareyama M, Satoh M, Hinoda Y, Seto M et al. (1999) Association of cyclin D1 expression with factors correlated with tumor progression in human hepatocellular carcinoma. J Gastroenterol 34: 486-493
79. Sherr CJ, Roberts JM (2004) Living with or without cyclins and cyclin-dependent kinases. Genes Dev 18: 2699-2711
80. Simpson DJ, Frost SJ, Bicknell JE, Broome JC, McNicol AM, Clayton RN et al. (2001) Aberrant expression of G(1)/S regulators is a frequent event in sporadic pituitary adenomas. Carcinogenesis 22: 1149-1154
81. Sonpavde G, Hutson TE, Berry WR (2006) Hormone refractory prostate cancer: management and advances. Cancer Treat Rev 32: 90-100
82. Sudo T, Irie A, Ishii D, Satoh E, Mitomi H, Baba S (2003) Histopathologic and biologic characteristics of a transitional cell carcinoma with inverted papilloma-like endophytic growth pattern. Urology 61: 837
83. Sumrejkanchanakij P, Eto K, Ikeda MA (2006) Cytoplasmic sequestration of cyclin D1 associated with cell cycle withdrawal of neuroblastoma cells. Biochem Biophys Res Commun 340: 302-308
84. Taplin ME, Balk SP (2004) Androgen receptor: a key molecule in the progression of prostate cancer to hormone independence. J Cell Biochem 91: 483-490
85. Temmim L, Ebraheem AK, Baker H, Sinowatz F (2006) Cyclin D1 protein expression in human thyroid gland and thyroid cancer. Anat Histol Embryol 35: 125-129
86. Tetsu O, McCormick F (1999) Beta-catenin regulates expression of cyclin D1 in colon carcinoma cells. Nature 398: 422-426
87. Trapman J (2001) Molecular mechanisms of prostate cancer. Eur J Cancer 37(Suppl 7): S119-S125
88. Tut VM, Braithwaite KL, Angus B, Neal DE, Lunec J, Mellon JK (2001) Cyclin D1 expression in transitional cell carcinoma of the bladder: correlation with p53, waf1, pRb and Ki67. Br J Cancer 84: 270-275
89. Xu Y, Chen SY, Ross KN, Balk SP (2006) Androgens Induce Prostate Cancer Cell Proliferation through Mammalian Target of Rapamycin Activation and Post-transcriptional Increases in Cyclin D Proteins. Cancer Res 66: 7783-7792